Promoting illiteracy in epigenetics: An emerging therapeutic strategy

Current Chemical Genomics

Volumn 5, Issue SPEC. ISSUE 1, 2011, Pages 48-50

  Wigle, Tim J ^a  

^a EPIZYME INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DNA METHYLTRANSFERASE; HISTONE DEACETYLASE; HYBRID PROTEIN; ROMIDEPSIN; VORINOSTAT;

DISEASE COURSE; DNA SEQUENCE; DRUG TARGETING; EDITORIAL; EPIGENETICS; HISTONE METHYLATION; HUMAN; HUMAN GENOME; LYMPHOMA; MELANOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL;

EID: 80455125854     PISSN: None     EISSN: 18753973     Source Type: Journal    
DOI: 10.2174/1875397301005010048     Document Type: Editorial

References (18)

1. Waddington CH. The epigenotype. Endeavour 1942: 18-20.
2. Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. Genes Dev 2009; 23: 781-3.
3. Michaeli J, Lebedev YB, Richon VM, Chen ZX, Marks PA, Rifkind RA. Conversion of differentiation inducer resistance to differentiation inducer sensitivity in erythroleukemia cells. Mol Cell Biol 1990; 10: 3535-40.
4. Richon VM, Webb Y, Merger R, et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci U S A 1996; 93: 5705-8.
5. Richon VM, Emiliani S, Verdin E, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 1998; 95: 3003-7.
6. Sorm F, Piskala A, Cihak A, Vesely J. 5-Azacytidine, a new, highly effective cancerostatic. Experientia 1964; 20: 202-3.
7. Friedman S. The effect of 5-azacytidine on E. coli DNA methylase. Biochem Biophys Res Commun 1979; 89: 1328-33.
8. Mack GS. To selectivity and beyond. Nat Biotechnol 2010; 28: 1259-66.
9. Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42: 181-5.
10. Sneeringer CJ, Scott MP, Kuntz KW, et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci USA 2010; 107: 20980-5.
11. Okada Y, Feng Q, Lin Y, et al. hDOT1L links histone methylation to leukemogenesis. Cell 2005; 121: 167-78.
12. Wang GG, Cai L, Pasillas MP, Kamps MP. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat Cell Biol 2007; 9: 804-12.
13. Ceol CJ, Houvras Y, Jane-Valbuena J, et al. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature 2011; 471: 513-7.
14. Hamamoto R, Silva FP, Tsuge M, et al. Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci 2006; 97: 113-8.
15. Chen MW, Hua KT, Kao HJ, et al. H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Res 2010; 70: 7830-40.
16. Liu F, Chen X, Allali-Hassani A, et al. Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. J Med Chem 2010; 53: 5844-57.
17. Kahl P, Gullotti L, Heukamp LC, et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 2006; 66: 11341-7.
18. Huang Y, Stewart TM, Wu Y, et al. Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin Cancer Res 2009; 15: 7217-28.